Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Completed · Phase 2

Conditions studied: Thyroid Neoplasms

In brief

This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.

Key facts

Study ID
NCT00094055
Run by
Pfizer
People needed
60
Starts
2004-09-01
Expected to finish
2009-01-01
Last updated by the study team
2012-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.